Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.94)
# 155
Out of 5,070 analysts
267
Total ratings
62%
Success rate
38.9%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterated: Buy | $1,282 | $869.72 | +47.40% | 31 | Oct 8, 2026 | |
| CLDX Celldex Therapeutics | Rated: Buy | $68 | $30.29 | +124.50% | 8 | Sep 22, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $132 → $152 | $113.46 | +33.97% | 12 | Sep 22, 2026 | |
| ROIV Roivant Sciences | Initiated Coverage: Buy | $51 | $34.92 | +46.05% | 1 | Sep 17, 2026 | |
| EVMN Evommune | Reiterated: Buy | $30 | $5.38 | +457.62% | 4 | Sep 9, 2026 | |
| ANAB AnaptysBio | Rated: Hold | n/a | $45.43 | - | 12 | Sep 8, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $328 → $326 | $234.33 | +39.12% | 17 | Sep 1, 2026 | |
| SEPN Septerna | Reiterated: Buy | $49 → $46 | $39.35 | +16.90% | 3 | Aug 16, 2026 | |
| ALMS Alumis | Reiterated: Buy | $44 | $6.70 | +556.72% | 6 | Aug 13, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $28 | $14.83 | +88.81% | 7 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $133 | $78.75 | +68.89% | 13 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $14.86 | +169.18% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $123 | $91.40 | +34.57% | 20 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $22.43 | +78.33% | 19 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $57 | $28.59 | +99.37% | 17 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $62 | $52.30 | +18.55% | 31 | Aug 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.43 | +249.65% | 4 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $79.09 | +89.66% | 10 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.38 | +262.32% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $39 | $12.36 | +215.53% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $4 | $3.77 | +6.10% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $13 → $19 | $10.32 | +84.11% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $0.9124 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $11.08 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $43.13 | n/a | 1 | Aug 8, 2023 |
argenx SE
Oct 8, 2026
Reiterated: Buy
Price Target: $1,282
Current: $869.72
Upside: +47.40%
Celldex Therapeutics
Sep 22, 2026
Rated: Buy
Price Target: $68
Current: $30.29
Upside: +124.50%
Kymera Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $132 → $152
Current: $113.46
Upside: +33.97%
Roivant Sciences
Sep 17, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $34.92
Upside: +46.05%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $30
Current: $5.38
Upside: +457.62%
AnaptysBio
Sep 8, 2026
Rated: Hold
Price Target: n/a
Current: $45.43
Upside: -
Ascendis Pharma
Sep 1, 2026
Reiterated: Buy
Price Target: $328 → $326
Current: $234.33
Upside: +39.12%
Septerna
Aug 16, 2026
Reiterated: Buy
Price Target: $49 → $46
Current: $39.35
Upside: +16.90%
Alumis
Aug 13, 2026
Reiterated: Buy
Price Target: $44
Current: $6.70
Upside: +556.72%
Cullinan Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $28
Current: $14.83
Upside: +88.81%
Aug 13, 2026
Reiterated: Buy
Price Target: $133
Current: $78.75
Upside: +68.89%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $14.86
Upside: +169.18%
Aug 13, 2026
Reiterated: Buy
Price Target: $123
Current: $91.40
Upside: +34.57%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $22.43
Upside: +78.33%
Aug 11, 2026
Reiterated: Buy
Price Target: $49 → $57
Current: $28.59
Upside: +99.37%
Aug 9, 2026
Reiterated: Hold
Price Target: $62
Current: $52.30
Upside: +18.55%
Jul 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.43
Upside: +249.65%
Jun 29, 2026
Reiterated: Buy
Price Target: $150
Current: $79.09
Upside: +89.66%
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $1.38
Upside: +262.32%
May 15, 2026
Reiterated: Buy
Price Target: $36 → $39
Current: $12.36
Upside: +215.53%
May 8, 2026
Reiterated: Hold
Price Target: $2 → $4
Current: $3.77
Upside: +6.10%
Mar 1, 2026
Reiterated: Hold
Price Target: $13 → $19
Current: $10.32
Upside: +84.11%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $0.9124
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $11.08
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $43.13
Upside: n/a